Evidence map›Paper›PMID 40136411›Full record

ArticleCurrent issues in molecular biology2025

Development of an Anti-Zearalenone Nanobody Phage Display Library and Preparation of Specific Nanobodies.

Ying Zeng, Yiying Hu, Ganying Chen, Qingqing Feng, Ruiting Wang, Zhilin Zhang, Jinxian Chen, Junbin Liao, Danrong Lin, Wei Zhu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current issues in molecular biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ying ZengSchool of Public Health, Southern Medical University, Guangzhou 510515, China.
Yiying HuSchool of Public Health, Southern Medical University, Guangzhou 510515, China.
Ganying ChenDepartment of Scientific Research Management, Guangzhou Center for Disease Control and Prevention (Guangzhou Health Supervision Institute), Guangzhou 510440, China.
Qingqing FengDepartment of Scientific Research Management, Guangzhou Center for Disease Control and Prevention (Guangzhou Health Supervision Institute), Guangzhou 510440, China.
Ruiting WangDepartment of Scientific Research Management, Guangzhou Center for Disease Control and Prevention (Guangzhou Health Supervision Institute), Guangzhou 510440, China.
Zhilin ZhangDepartment of Scientific Research Management, Guangzhou Center for Disease Control and Prevention (Guangzhou Health Supervision Institute), Guangzhou 510440, China.
Jinxian ChenDepartment of Scientific Research Management, Guangzhou Center for Disease Control and Prevention (Guangzhou Health Supervision Institute), Guangzhou 510440, China.
Junbin LiaoSchool of Public Health, Southern Medical University, Guangzhou 510515, China.
Danrong LinDepartment of Scientific Research Management, Guangzhou Center for Disease Control and Prevention (Guangzhou Health Supervision Institute), Guangzhou 510440, China.
Wei ZhuSchool of Public Health, Southern Medical University, Guangzhou 510515, China.ORCID 0000-0001-5796-4167

Funding

Basic Research Priorities Program of Guangzhou 2024A03J0558
6 · The paper itself

Abstract

Zearalenone (ZEN), a toxic estrogenic mycotoxin in cereals, threatens human and animal health through reproductive, immune, and cytotoxic effects, necessitating sensitive detection methods. While nanobodies offer advantages over conventional antibodies for on-site ZEN detection, their application remains unexplored. This study aimed to develop an anti-ZEN nanobody derived from an anti-ZEN phage display nanobody library. An alpaca was immunized with a ZEN-bovine serum albumin (ZEN-BSA) antigen, achieving peak serum antibody titers (1:25,600) following four immunizations. A high-capacity phage display nanobody library (1.0 × 10

Indexed as

biopanningnanobodyphage displayprokaryotic expressionzearalenone

Identifiers

PMID40136411
PMCPMC11940844

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.